Long-Term Safety of Tirzepatide (Mounjaro): Relationship Between Duration of Use and Adverse Events Compared With Semaglutide and Liraglutide
Journal of Clinical Endocrinology and Metabolism · 2026
DOI: 10.52338/jocem.2026.5500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Endocrinology and Metabolism, 2026. Verfasst von Thiago A. Rochetti Bezerra und 39 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
Tirzepatide is an innovation in the treatment of type 2 diabetes and obesity, combining GIP and GLP-1 agonism, promoting glycemic control, weight reduction, and sustained metabolic benefits.Clinical and pharmacovigilance studies elucidate its efficacy and the temporal behavior of adverse effects.
Objectives
To analyze the efficacy and safety of tirzepatide, correlating adverse events with duration of use in patients with type 2 diabetes and obesity; to describe the main events, compare frequencies between clinical profiles, and evaluate their relationship with treatment duration.Methodology: Integrative review according to PRISMA guidelines, including publications from 2020-2025 in PubMed, Scopus, Web of Science, and Google Scholar databases.Thirty-two studies (clinical trials, observational studies, and pharmacovigilance studies) were selected.The analysis was descriptive and comparative, considering study type, treatment duration, and pattern of adverse events.
Results
Tirzepatide showed superiority over GLP-1 agonists alone, with mean reductions in HbA1c >2% and clinically significant weight loss, maintained in the long term.The most common adverse events were gastrointestinal, mild, and self-limiting, predominantly occurring in the first weeks of titration and decreasing with continued use.Final considerations: The safety profile is favorable, with rare serious events and predictable physiological adaptation.Tirzepatide is established as an effective, safe, and cost-effective option for the integrated management of type 2 diabetes and obesity.
Zitieren
APA
Bezerra, T. A. R., Siqueira, G. G. V., Siqueira, M. C. G., Tanaka, A. P. D. L., Fukushima, V. I., Lisboa, M. B., Medeiros, J. P. A. D., Mafetano, A. P. V. P., Amadeu, E. L., Marcondes, G. C. C., Ervilha, A. L. N., Ventura, M. B. M., Silva, J. F. C., Lima, C. A. P., Bitolo, G. C., Rodrigues, M. O. D. O. F., Yamashiro, G. C., Occulate, L. M., Tudela, R. R., …, & Furtado, D. C. (2026). Long-Term Safety of Tirzepatide (Mounjaro): Relationship Between Duration of Use and Adverse Events Compared With Semaglutide and Liraglutide. Journal of Clinical Endocrinology and Metabolism. https://doi.org/10.52338/jocem.2026.5500
Vancouver
Bezerra TAR, Siqueira GGV, Siqueira MCG, Tanaka APDL, Fukushima VI, Lisboa MB, et al. Long-Term Safety of Tirzepatide (Mounjaro): Relationship Between Duration of Use and Adverse Events Compared With Semaglutide and Liraglutide. Journal of Clinical Endocrinology and Metabolism. 2026. doi:10.52338/jocem.2026.5500
BibTeX
@article{Bezerra2026,
author = {Bezerra, Thiago A. Rochetti and Siqueira, Giovanna Guimarães Vilarinho and Siqueira, Marcia Cristina Guimarães and Tanaka, Ana Paula de Lima and Fukushima, Vanessa Iukari and Lisboa, Matheus Barros and Medeiros, João Pedro Arraes de and Mafetano, Ana Paula Valente Pinho and Amadeu, Elisa Lavezzo and Marcondes, Giulia Candido Campos and Ervilha, Ana Laura Nogueira and Ventura, Maria Beatriz Mendonça and Silva, Julienne F. C. and Lima, Christopher Aquino Pereira and Bitolo, Giovana Clausson and Rodrigues, Maria Olivia de Oliveira Futuro and Yamashiro, Giovana Casarini and Occulate, Liliana Martins and Tudela, Rubens Rodrigues and Machado, Larissa Bauer and Mendonça, Carlos Henrique B. Figueiredo de and Couto, Marco Aurélio Silva and Sganzella, Gianluca F. Castro and Januário, Julia Adelaide and Santos, Isabelle P. and Borges, Michelli D. Martins and Bueno, Rafaela Gonçalves and Malaquias, Délio T. Martins and Cunha, Wellington da Silva P. da and Mariz, Diego Paulino and Carvalho, Roselene de Oliveira and Consolin, Elis Muraro and Batista, Regilane da Silva and Dorna, Bruno E. Silva and Carvalho, Joseilton Vilela de and Oliveira, Isabeli Gomes de and Fagundes, Lorena Almeida and Lotf, Pedro F. Morandini and Lousada, Talita L. de Castro and Furtado, Daniella Campos},
title = {Long-Term Safety of Tirzepatide (Mounjaro): Relationship Between Duration of Use and Adverse Events Compared With Semaglutide and Liraglutide},
journal = {Journal of Clinical Endocrinology and Metabolism},
year = {2026},
doi = {10.52338/jocem.2026.5500}
}
EUVIMED